As Brazil faces the annual surge in dengue cases, health authorities have reported 489,100 probable cases and 368 confirmed deaths so far in 2026. The rainy season has amplified the spread of the Aedes aegypti mosquito, with four states—Minas Gerais, Goiás, Tocantins, and São Paulo—accounting for more than half of all notifications. In Belo Horizonte, the city has intensified its mosquito control efforts, including home visits and public guidance, as the city also remains alert for zika and chikungunya outbreaks.
These figures represent a critical public health challenge, demanding a coordinated response between government agencies and citizens to eliminate mosquito breeding sites. The situation shows the persistent threat of arboviruses in Brazil and the urgent need for strong prevention strategies as climate patterns and population immunity continue to change.
The Projected Surge: Epidemiological Models and Climate Influence
A comprehensive analysis presented last week by a consortium of over 130 specialists from eight countries, submitted to the Ministry of Health, projects that Brazil could see as many as 860,000 probable dengue cases in 2027. This forecast, presented during the “Preparation for the Dengue Season 2027” webinar, suggests a scenario similar to 2025 and 2026, despite the anticipated impact of a super El Niño event during the upcoming summer.
The models, developed by institutions including the Oswaldo Cruz Foundation (Fiocruz), the Getulio Vargas Foundation (FGV), Mosqlimate, and InfoDengue, are not merely statistical predictions. They represent a sophisticated tool for public health managers, integrating diverse data streams to anticipate transmission patterns and allocate resources effectively. “In three editions, the challenge has grown from a handful of teams to a global community working openly to transform dengue data into predictions that public health managers can actually use,” said Flávio C. Coelho, a researcher with FGV and Mosqlimate.
The projection for 2027, with a central estimate of 860,000 cases, carries a significant margin of uncertainty. The 80% confidence interval spans from 560,000 to 1.6 million cases, with a peak of approximately 40,000 cases anticipated in April. This wide range reflects the inherent complexity of forecasting infectious diseases, especially in the face of climate variability. Between 2006 and 2024, the number of Brazilian micro-regions under epidemic levels of dengue more than doubled, a trend strongly linked to rising temperatures and prolonged thermal anomalies.
Regional Disparities and the El Niño Effect
The national projection masks significant regional variations. Six states are identified with a growing trend: Mato Grosso do Sul, Paraná, Rio de Janeiro, Sergipe, Acre, and Minas Gerais. Other states are expected to see stability or a reduction in cases relative to the previous season.
El Niño, a climate pattern known for increasing sea surface temperatures in the central and eastern Pacific, is a key part of this forecast. The Minister of Health, Alexandre Padilha, has linked the expected surge to a combination of the El Niño phenomenon and the epidemiological dynamics of dengue. The disease saw a drop in cases over the past two years, leaving a larger portion of the population without immunity to the currently circulating serotypes. This susceptibility, combined with the environmental conditions fostered by El Niño, creates a high-risk environment.
The potential impact varies dramatically by region. In a scenario of strong El Niño, estimates indicate increases between September of this year and the beginning of 2027: 49.1% in the Northeast, 68.9% in the North, 84.9% in the Southeast, 98.4% in the Central-West, and 138.2% in the South. This regional breakdown is crucial for directing targeted public health interventions, ensuring that areas facing the highest potential surge are prepared with enhanced surveillance, vector control, and clinical management capacity.
Preventing Mosquito Breeding at Home
- Brazil is currently experiencing a major dengue outbreak, with nearly half a million cases reported this year, driven by the rainy season and the proliferation of the Aedes aegypti mosquito.
- Experts predict the situation could worsen next year, with potentially up to 860,000 cases, largely due to climate factors (El Niño) and a population with lower immunity from recent years with fewer cases.
- The best defense remains individual and community action: eliminating standing water around homes to prevent mosquito breeding and seeking medical attention promptly if symptoms like fever, severe body pain, or rash develop.
Estimating Chikungunya Cases in Brazil
The disease burden is not limited to dengue. For the first time, the multi-country research consortium has incorporated projections for chikungunya, another mosquito-borne illness. The models, using 11 different approaches, estimate more than 90,000 probable chikungunya cases in Brazil for 2027. This figure surpasses the 76,000 cases recorded in the 2025-2026 season but remains below the 127,000 seen in 2024-2025.
The regional trends for chikungunya mirror those of dengue in many areas. Mato Grosso do Sul is identified as the state with the highest incidence of the disease in the country and is also projected to see an increase. Other states facing potential growth include Mato Grosso, São Paulo, all three states in the South, and parts of the Northeast. Both diseases share the same vector, Aedes aegypti, meaning that prevention efforts targeting the mosquito are effective against both pathogens. This convergence of threats places an even greater strain on public health systems and necessitates a unified approach to vector control.
Vaccination Strategy: Public and Private Options
As the threat looms, vaccination has emerged as a critical tool for preventing severe disease. The Brazilian Unified Health System (SUS) currently offers the Qdenga vaccine, manufactured by Takeda, for adolescents aged 10 to 14. In 2024, the Ministry of Health purchased approximately 10 million doses of Qdenga for R$ 1.3 billion. The vaccine is also available through the private healthcare network for a broader age range, from 4 to 60 years, as per its Anvisa registration.
There is an active effort to expand the public health arsenal. Minister Padilha has stated that the government is working to reintroduce the Butantan-DV vaccine into the SUS. This vaccine, developed by the Butantan Institute, was approved by Anvisa in November 2025 for individuals aged 12 to 59. The Ministry had signed a contract in December 2025 to purchase 3.9 million doses for R$ 367.9 million, though its implementation in the public system remains pending. Studies indicate that the protection conferred by the Butantan-DV vaccine lasts for about five years. The availability of two distinct vaccines provides flexibility, but the primary goal remains ensuring equitable access to immunization for those most at risk of severe outcomes, thereby reducing the strain on hospitals and lowering mortality rates.
| Parameter | 2026 Data (Reported) | 2027 Projection (Estimated) |
|---|---|---|
| Dengue Cases (Probable) | 489,100 (Brazil, 2026) | 860,000 (Central Estimate) |
| Dengue Deaths (Confirmed) | 368 (Brazil, 2026) | Not Projected |
| Chikungunya Cases (Probable) | 76,000 (2025-2026 Season) | 90,000 (Estimate) |
| Peak Monthly Dengue Cases | Not Specified | 40,000 (Projected for April 2027) |
The Climate Connection: How Environmental Changes Drive Transmission
The rise in dengue and chikungunya cannot be understood without considering the influence of climate change. Rising global temperatures and more frequent extreme thermal anomalies are breaking down natural barriers and accelerating the spread of infectious diseases in Brazil. A Fiocruz study found that between 2006 and 2024, the number of Brazilian micro-regions experiencing epidemic levels of dengue more than doubled, with prolonged thermal anomalies being the variable that best explains the long-term increase in incidence rates.
Heat directly impacts the mosquito’s life cycle. “They lay eggs with a very resistant shell that can remain in nature for years and hatch when there is humidity and high temperature,” explained an expert in the piece. “These mosquitoes can be born already infected. When it’s very hot, they have to flap their wings faster to fly.” This accelerated metabolism shortens the pathogen’s extrinsic incubation period and increases the biting rate of female mosquitoes, significantly boosting transmission potential. Climate change also affects human behavior and settlement patterns, creating new ecological niches for the vector to thrive. This complex interplay between climate, vector, and virus makes dengue a persistent and evolving challenge for public health.
Seeking Medical Attention for Symptoms
The Qdenga and Butantan-DV vaccines are not for everyone. Individuals with a history of severe allergic reaction (anaphylaxis) to a previous dose of the same vaccine or to any of its components should not be vaccinated. As with any medical intervention, potential side effects exist, and individuals should discuss their complete medical history with a healthcare provider before vaccination.
Anyone presenting with a fever accompanied by two or more of the following symptoms—severe headache, pain behind the eyes, muscle and joint pains, nausea, vomiting, swollen glands, or rash—should seek medical evaluation. Symptoms of warning signs, which indicate severe dengue and require immediate emergency care, include severe abdominal pain, persistent vomiting, rapid breathing, bleeding gums or nose, fatigue, restlessness, and pale skin. Early clinical management can significantly reduce the risk of fatal complications.
Conclusion: A Call for Vigilance and Collective Action
The data paints a clear picture: dengue remains a formidable public health adversary in Brazil. The combination of climate-driven environmental changes, population dynamics, and viral evolution creates a complex situation that demands sustained, evidence-based action.
The path forward requires a multi-pronged strategy. It involves strengthening epidemiological surveillance to detect outbreaks early, intensifying vector control campaigns that rely on community participation to eliminate breeding sites, and strategically deploying vaccination programs to protect the most vulnerable. The work of the research consortium provides a powerful scientific foundation, but its value lies in its translation into public policy and on-the-ground intervention. The question that remains is not if the cases will rise, but how effectively the health system and society can respond to mitigate the human cost of this ongoing epidemic.
References
- Agência Brasil. (2026). “País pode chegar a 860 mil casos prováveis de dengue em 2027.”
- A Crítica de Campo Grande. (2026). “Mato Grosso do Sul está entre os estados com previsão de alta nos casos de dengue e chikungunya em 2027.”
- Muita Informação. (2026). “Mudanças climáticas impulsionam avanço de dengue, Oropouche e fungos hospitalares no Brasil.”
- Poder360. (2026). “Saude Alerta Para Alta Da Dengue E Tenta Retomar Vacina Butantan Dv.”
- World Health Organization (WHO). (n.d.). “Dengue and severe dengue.” Retrieved from
